of angiogenesis. These phenotypes induced by MYC inactivation are surprisingly similar to those resulting from the loss in function of miR-17-92, a MYC target gene known to regulate multiple aspects of tumorigenesis, such as proliferation, survival, and angiogenesis.
Therefore, we speculated that miR-17-92 could mediate MYC oncogene addiction. Indeed, we found miR-17-92 expression rescued many of the phenotypes associated with MYC inactivation. Furthermore, we discovered that miR-17-92 can target several histone modifiers, such as Sin3 transcription regulator family member B (Sin3b), high mobility group box transcription factor 1 (Hbp1), suppressor of variegation 4-20 homolog 1 (Suv420h1), and B cell translocation gene 1 (Btg1), as well as the apoptosis mediator Bcl2-like 11 (Bcl2l11, also known as Bim). Sin3b and Hbp1 coordinately recruit histone deacetylases to downregulate the expression of proliferation-related genes, resulting in cell cycle exit and senescence. Suv420h1 can regulate chromatin compaction and senescence by methylating histone H4 lysine 20. Btg1 can also regulate chromatin state, senescence, and differentiation by activating protein arginine methyltransferase 1 (Prmt1) to methylate histone H4 arginine 3. Thus, through coordinately regulating multiple epigenetic programs, these histone modifiers induce proliferative arrest and senescence upon MYC inactivation. By modulating the expression of these histone modifiers and the apoptosis regulator, Bim, miR-17-92 can block the normal cellular safety switch and sustain the neoplastic state of MYC-driven tumors. Upon the inactivation of MYC, the downregulation of miR-17-92 results in the induction of these target genes, which can drive senescence, apoptosis, and differentiation. Hence, MYC inactivation appears to reset the cellular safety switch and results in tumor collapse [7] .
Although we observed our results in MYC-induced tumors, we speculate that other oncogenic drivers are likely to operate through similar if not identical mechanisms. For example, we have observed that suppression of RAS or BCR-ABL similarly activates senescence and apoptosis programs. This safety switch model supported by our experimental observations provides a possible general mechanistic explanation for the phenomenon of oncogene addiction.
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